A heated debate is unfolding within the American Medical Association (AMA) as delegates grapple with a crucial decision: Should the AMA become a 'public-facing megaphone' on vaccines, or should they focus on restoring the original CDC committee? This is a complex issue with far-reaching implications, and it's a topic that has divided opinions.
The AMA House of Delegates met in National Harbor, Maryland, to discuss this very question. The debate centered around two options: forming a new AMA vaccine advisory committee or fighting to bring back the disbanded Advisory Committee on Immunization Practices (ACIP).
But here's where it gets controversial...
In June, a controversial move by HHS Secretary Robert F. Kennedy Jr. saw all 17 members of the ACIP ousted and replaced with individuals who shared his vaccine skepticism. This action sparked a chain of events, leading to the current dilemma facing the AMA.
Dr. Dave Cundiff, a delegate representing the American Association of Public Health Physicians (AAPHP), proposed a draft policy statement. It called for the AMA to bring together key stakeholders and develop evidence-based vaccine recommendations. However, not everyone was on board with this idea.
And this is the part most people miss...
The draft resolution suggested that the AMA establish itself as a trusted, centralized source for science-based vaccine guidance. While some delegates supported this, others, like Dr. Jason Goldman, president of the American College of Physicians (ACP), warned against it. He cited a conflict of interest, given the ACP's previous emergency resolution calling for Kennedy to reverse his decision to disband the original ACIP.
Dr. Goldman argued that the AMA taking on an 'alternative' ACIP role would be costly and complex. He estimated the cost to be in the hundreds of millions, and highlighted the potential impact on insurance coverage under the Affordable Care Act, which is tied to ACIP recommendations.
Instead, Dr. Goldman urged the AMA to focus on unseating Kennedy's appointed committee and restoring the science-driven ACIP. He requested that the draft policy be referred to the Board of Trustees for further consideration.
AMA board member Dr. Sandra Fryhofer, a former ACIP liaison, agreed. She emphasized the importance of restoring these entities to their original intent.
Dr. Cundiff acknowledged the shared goals of both sides, expressing a desire to see the old ACIP restored. However, he acknowledged the challenges ahead.
As a result of the ACP's resolution, the AMA has already begun collaborating with national medical specialty societies to determine the best course of action.
Dr. Virginia Dato, a board-certified pediatric and public health physician, stressed the need for evidence-based recommendations free from conflicts of interest. She highlighted the potential reliability issues arising from the loss of experienced ACIP members and dedicated CDC scientific staff.
With multiple groups, including specialty societies and state governors, issuing separate vaccine recommendations, Dr. Dato emphasized the need for a coordinated, transparent process to guide decision-making for the millions relying on these guidelines.
So, what's the solution?
Dr. Andrew Rudawsky, an Ohio delegate, speaking on behalf of the Great Lakes States Coalition, suggested referring the resolution to the Board. He acknowledged the short-sightedness of dismissing the original ACIP but cautioned against 'burning the institution to the ground.'
Dr. Abhishek Dharan, a delegate representing the Resident and Fellows Section, offered a more direct assessment. He believed that returning to the old ACIP was unlikely, given the fundamental changes in the nation's landscape. Instead, he proposed that the AMA consider how vaccination recommendations should be made in the future, suggesting a role for the 'house of medicine' rather than government influence.
The reference committee will present its final report on Monday, summarizing the debate and offering its own recommendations. This is a critical moment for the AMA and the future of vaccine guidance in the United States.
